11 Best Cancer Stocks to Invest In Now

Page 2 of 10

9. Arvinas, Inc. (NASDAQ:ARVN)

Arvinas Inc. (NASDAQ:ARVN) is one of the best cancer stocks to invest in now. On February 24, Arvinas Inc. (NASDAQ:ARVN) delivered solid fourth-quarter and full-year results that affirmed progress across pipeline development.

During the year, the company submitted its first new drug application, setting the stage for potential FDA approval of a PROTAC degrader. The company has already presented topline results for ARV-806, affirming robust and differentiated activity in models of KRAS G12D-mutated cancer. It is also progressing with dose escalation in the Phase 1 trial of ARV-393 in patients with non-Hodgkin’s lymphoma (NHL).393.

“With four ongoing clinical trials across our oncology and neurology portfolios, including the recently initiated first-in-human trial of our polyQ-AR degrader, ARV-027, we believe we have the potential to bring truly differentiated treatments to millions of patients in areas of significant unmet medical need,” said Randy Teel, Ph.D., President and CEO of Arvinas

Full year 2025 revenue came in at $262.6 million, down from $263.4 million a year ago. Fourth quarter revenue dropped to $9.5 million compared to $59.2 million in the same quarter of the prior year. The decrease was attributed to lower revenue from the Novartis license agreement.

Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapies that degrade disease-causing proteins rather than just inhibiting them. Utilizing its proprietary PROTAC® (Proteolysis-Targeting Chimera) platform, the company targets “undruggable” proteins to treat serious, debilitating diseases, including prostate and breast cancers, as well as neurodegenerative disorders.

Page 2 of 10